Genomic Vision strengthens team

Appoints chief finance officer and vice president of research and development

Genomic Vision, a biotechnology company dedicated to DNA analysis with an innovative molecular combing nanotechnology, has appointed Erwan Martin as chief financial officer and Emmanuel Conseiller as vice president of research and development.

Prior to joining Genomic Vision, Martin was cfo at Cytomics Pharmaceuticals (2003–2008), a biopharmaceutical company he co-founded with Dominique Thomas (Research Director at the CNRS Centre for Molecular Genetics, Gif-sur-Yvette) and for which he led the first rounds of financing. Prior to this he worked for 10 years as a consultant for Syndex, an auditing firm.

Conseiller joined Genomic Vision in 2009 after working for more than 17 years as a senior manager at sanofi-aventis (primarily within the oncology division). He is a pioneer in the application of functional genomics to drug discovery (from drug target screening to clinical trials) and has designed and led several projects for drug screening (small molecules and gene therapy) in the fields of tumour suppression, DNA replication and tumour metabolism. He holds a PhD from Pierre and Marie Curie University, Paris. In 1997, he won the Rhone-Poulenc Rorer Research Prize for his work on the development of chimeric tumour suppressors for gene therapy of cancer.

You may also like

Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
Research & Development

ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology

Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development

Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease

Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates
Design & Build

Entries closed: what’s next for the Cleanroom Technology Awards?

With entries now closed, attention turns to the next phase of the awards programme
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities

The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
Subscribe now